Charles M. Warden - 10 Jun 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Director
Issuer ticker: OCUL
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 17:23:27 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Charles M. Warden

Key filing fact

Charles M. Warden filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 12 Jun 2026.

Key facts

This page summarizes Charles M. Warden's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 17:23.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001354802 Primary reporting owner

Warden Charles M

Relationship: Director
Address: C/O OCULAR THERAPEUTIX, INC., 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Charles M. Warden
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Award

Transaction value
Shares: +14,000
Change %: +16%
Price: $0.000000^*
Shares after: 100,464
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +44,000
Change %
Price: $0.000000^*
Shares after: 44,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,000
Exercise price: $8.74
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

Footnote F2

Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.